Navigation Links
Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
Date:2/16/2011

SAN DIEGO, Feb. 16, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the completion of a public offering of 6,900,000 shares of its common stock, including 900,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. The shares were sold at a public offering price of $11.25 per share, resulting in aggregate gross proceeds to Optimer of $77.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Optimer.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Jefferies & Company, Inc. acted as the sole book-running manager for the offering. Baird, Canaccord Genuity Inc., JMP Securities, Needham & Company, LLC, and ThinkEquity LLC acted as co-managers for the offering.  

Optimer anticipates using the net proceeds from the offering to prepare for the potential commercial launch of fidaxomicin in the United States, if approved, as well as for research and development activities, potential in-licenses or acquisitions, working capital and other general corporate purposes.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A final prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at Prospectus_Department@Jefferies.
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
3. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
4. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
9. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 CollabRx, Inc. (NASDAQ: ... therapeutic decision-making in oncology, today announced that it will ... to discuss the Company's financial results for the first ... about the business in the current fiscal year. , ... on Thursday, August 14, 2014, at 5 p.m. EDT ...
(Date:7/31/2014)... Held at the Stanford Cancer Center, the ... the disease and its treatment. Survivors will find information ... as updates on the state-of-the-art with respect to newer ... organizing this educational opportunity,” says KCA CEO Bill Bro, ... colleagues have put together a program that balances the ...
(Date:7/31/2014)... 31, 2014 “Rapid technological advances ... the U.S., increasing unemployment, depressing American consumer spending ... is a Catch 22—we need automated manufacturing if ... fewer jobs,” says economist and corporate relocation expert ... Top 10 Pro-Business States for 2014, co-published with ...
(Date:7/31/2014)... 2014 Boston’s Adult Stem Cell Technology ... innovative adult stem cell biotechnologies. Currently the company ... three additional patent applications currently under examination by the ... address two of the most vexing problems in adult ... stem cells are difficult to identify; and they have ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3
... BUDAPEST, Hungary, August 21 ChemAxon, a software,solutions ... Instant JChem, it,s desktop application for working with ... The version 2 release brings,forms and form building, ... Instant JChem Personal edition features the vast,majority of ...
... Companies, PITTSBURGH, Aug. 21 The Pittsburgh ... region,s life,sciences industry on a fast track for ... of $450,000 in three companies: Applied Computational,Technologies, Separation ... committed to identifying and making investments in promising,life ...
... Dr. Lanza for ,Courage Under Fire, WORCESTER, ... Bulletin Board: ACTC) is proud to announced that ... and Scientific,Development, has been recognized for his research ... the current issue of PharmaVOICE (cover,story July/August issue). ...
Cached Biology Technology:Instant JChem 2.0 Released: Instant JChem Personal Free for All Users 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
(Date:7/31/2014)... New research, supported by the National Science Foundation ... permafrost uniformly accelerates atmospheric warming, indicating instead that ... they emit into the atmosphere. , The ... Nature , focuses on thermokarst lakes, which occur ... fill with melted fresh water, converting what was ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
(Date:7/31/2014)... An experimental vaccine protected 100 percent of animal models ... difficile , which causes an intestinal disease that kills ... of print in Infection and Immunity . ... and non-human primates against the purified toxins produced by ... orogastric spore infection, a laboratory model that mimics the ...
Breaking Biology News(10 mins):Certain Arctic lakes store more greenhouse gases than they release 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3C. difficile vaccine proves safe, 100 percent effective in animal models 2
... in humanity,s greatest achievements but scientists have found that working ... chimpanzees. A series of trials by scientists found ... also understand the need to help a partner perform their ... were given tools to get grapes out of a box. ...
... known risk factor for back pain and disc disease. ... Annual Meeting of the American Academy of Orthopaedic Surgeons ... in 6,779 patients undergoing treatment for spinal disorders with ... each patient,s age, gender, weight, smoking history, assessment of ...
... Stingrays living in one of the world,s most famous ... the Cayman Islands have profoundly changed their ways, ... on marine wildlife, reports a new study published March ... Researchers from Nova Southeastern University,s Guy Harvey Research ...
Cached Biology News:Origins of human teamwork found in chimpanzees 2Origins of human teamwork found in chimpanzees 3Tourist-fed stingrays change their ways 2
... Intended Use: Vision Mount is formulated for ... producing alcohol soluble OR alcohol insoluble end products. , ... ... used with chromogens such as Fast-Red or AEC that require ...
... very potent Rnase free Ribonuclease ... a broad range of temperatures ... does not inhibit SP6, T7, ... and M-MLV reverse transcriptase or ...
... The BioLogic Maximizer kit, 110 to ... pH monitoring and doubles flow rates ... chromatography systems. The kit includes the ... mixer, starter kit, tubing kit, system ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: